Previous section Next section
FIBRINOLYSIS
Body_ID: HC006027
The fibrinolytic system also limits excessive fibrin formation
Body_ID: HC006030
page 74
0
page 75
Body_ID: P0075
The coagulation system acts to form fibrin; the fibrinolytic system acts to limit excessive formation of fibrin (both intra- and extravascular) through plasmin-mediated fibrinolysis. Circulating plasminogen binds to fibrin via lysine-binding sites; it is converted to active plasmin by plasminogen activators. Tissue-type plasminogen activator (tPA) is synthesized by endothelial cells; it normally circulates in plasma in low basal concentrations (5 ng/mL), but is released into plasma by stimuli that include venous occlusion, exercise, and epinephrineView drug information. Together with plasminogen, it binds strongly to fibrin, which stimulates its activity (the Km for plasminogen decreases from 65 to 0.15μmol/L in the presence of fibrin), thereby localizing plasmin activity to fibrin deposits. Excessive tPA activity in plasma is normally prevented by an excess of its major inhibitor, plasminogen activator inhibitor type 1 (PAI-1), which is synthesized by both endothelial cells and hepatocytes. Urinary-type plasminogen activator (uPA) circulates in plasma both as an active single-chain precursor form, uPA (scuPA, pro-urokinase) and as a more active two-chain form (tcuPA, urokinaseView drug information). One activator of scuPA is surface-activated coagulation factor XII, which therefore links the coagulation and fibrinolytic systems. The major components of the fibrinolytic system are illustrated in Table 6.4 and Figure 6.7.
Body_ID: P006042
Excessive formation of plasmin is normally prevented by:
  • binding of 50% of plasminogen to histidine-rich glycoprotein (HRG);
  • rapid inactivation of free plasmin by its major inhibitor, α2-antiplasmin.
Body_ID: P006043
The physiologic importance of PAI-1 and α2-antiplasmin is illustrated by the increased bleeding tendency that is associated with the rare cases of their congenital deficiencies (see Table 6.1); the excessive plasma plasmin activity which results from the deficiencies has the effect of lysing hemostatic plugs.
Body_ID: P006044
Body_ID: T006004
Table 6-4. Properties of fibrinolytic system components.
Body_ID: None
Properties of fibrinolytic system components
Body_ID: T006004.50
Component (synonym)Molecular weightPlasma concentration (mg/dL)
Body_ID: T006004.100
Plasminogen920000.2
Body_ID: T006004.150
Tissue-type plasminogen activator, tPA650005 (basal)
Body_ID: T006004.200
Urinary-type plasminogen activator   type 1, uPA5400020
Body_ID: T006004.250
Plasminogen activator inhibitor   type 1, PAI-148000200
Body_ID: T006004.300
Antiplasmin (α2 antiplasmin)70000700
Body_ID: T006004.350
Body_ID: T006004
Body_ID: None
THROMBOLYTIC TREATMENT IN MYOCARDIAL INFARCTION
Body_ID: B006008
Occlusion of a coronary artery by thrombus causes death of that part of the heart muscle which is supplied by the artery (myocardial infarction). In acute myocardial infarction, the patient typically experiences severe, substantial chest pain. Many such patients are candidates for thrombolytic treatment with a plasminogen activator drug, given intravenously (there are some exceptions). Prompt thrombolysis dissolves the coronary artery thrombus, reduces the size of the infarct, and reduces the risk of complications, including death and heart failure. AspirinView drug information is also given routinely in acute myocardial infarction, to inhibit the platelet component of the developing coronary artery thrombus.
Body_ID: PB06019
Comment. Thrombolytic drugs include tissue-type and urinary-type plasminogen activators (tPA and uPA) (Fig. 6.7), produced by recombinant gene technology, or their synthetic variants. Worldwide, the most commonly used thrombolytic drug is streptokinaseView drug information (a plasminogen activator produced by streptococci), because of its lower cost. All thrombolytic drugs can cause bleeding (see Table 6.1), as a result of lysis of hemostatic plugs in addition to the target thrombi.
Body_ID: PB06020
Body_ID: P006045
Body_ID: F006007
Figure 6.7 The fibrinolytic system. Plasminogen can be activated to plasmin by uPA (urokinaseView drug information), tPA, or streptokinaseView drug information. uPA and tPA are inhibited by plasminogen activator inhibitor type 1 (PAI-1). Plasmin is inhibited by antiplasmin. Plasmin degrades fibrin to fibrin degradation products (FDP). HMWK, high-molecular-weight kininogen; scuPA, pro-urokinase; tcuPA, urokinase; tPA, tissue-type plasminogen activator.
Body_ID: P0076
Previous section
Bar end Bar end
Next section
Copyright © 2007 Elsevier Inc. All rights reserved. Read our Terms and Conditions of Use and our Privacy Policy.
For problems or suggestions concerning this service, please contact: studentconsult.help@elsevier.com